is the new PCSK9 pill ready for prime time??
this past July, The FDA approved enclicitide, a new oral proprotein convertase subtilisin–kexin type 9 ( PCSK9) inhibitor that goes by trade name Lipfendra , based on the CORALreef Lipids study ; it has a price of $315 for a 30-day supply by Merck: see lipid PCSK9 oral NEJM2026 in dropbox or DOI: 10.1056/NEJMoa2511002 Details: -- the CORALreef Lipids study was a multinational, double-blind, randomized, placebo-controlled drug company-sponsored trial that enrolled 2909 adult participants in the intention-to-treat population, where 1935 received enlicitide and 969 received placebo -- this study involved 168 sites in 14 countries (including the US, UK, Italy, South Africa, Colombia, Japan, Argentina, Spain, and China) -- the participants had a history of a major atherosclerotic cardiovascular disease event (which included acute coronary syndrome, coronary revascularization, MI, ischemic stroke, cerebrovascular arterial revascularization, and peripheral arterial disease with a histo...